Abivax S.A. (ABVX) stock
ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
$90.20−1.24 (-1.36%)
Close on Nov 12, 2026Market cap $7.08BP/E –Yield –
Abivax r&d expenses
Research and development expenses are spending on new products and technology.
Abivax's R&D Expenses for the twelve months ending Jun 30, 2026 was €207.69M, up 29.9% year over year. For fiscal 2025 it was €177.76M, up 21.3% from the year before. The highest annual figure on record is €177.76M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €177.76M | +21.3% |
| FY2024 | Dec 31, 2024 | €146.53M | +42.0% |
| FY2023 | Dec 31, 2023 | €103.18M | +113.6% |
| FY2022 | Dec 31, 2022 | €48.30M | +1.1% |
| FY2021 | Dec 31, 2021 | €47.78M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €58.34M | +51.0% |
| Q1 FY2026 | Mar 31, 2026 | €49.54M | +26.1% |
| Q4 FY2025 | Dec 31, 2025 | €44.40M | +15.0% |
| Q3 FY2025 | Sep 30, 2025 | €55.42M | +28.0% |
| Q2 FY2025 | Jun 30, 2025 | €38.65M | +33.7% |
| Q1 FY2025 | Mar 31, 2025 | €39.30M | +10.0% |
| Q4 FY2024 | Dec 31, 2024 | €38.60M | – |
| Q3 FY2024 | Sep 30, 2024 | €43.29M | – |
| Q2 FY2024 | Jun 30, 2024 | €28.91M | – |
| Q1 FY2024 | Mar 31, 2024 | €35.74M | – |
See a number that looks wrong?